Highlights Immunic, Inc.

Equities

IMUX

US4525EP1011

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
1.295 ^USD	+1.17%		+1.97%	-13.67%

05-08	Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08	Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	04-30	CI
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	03-21	MT
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	11-21	MT
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	11-02	CI
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	15/10/23	CI
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis	09/10/23	CI
Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis	17/08/23	CI
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders	04/05/23	CI
Immunic, Inc. Reports Positive Data from Maintenance Phase of its Phase 2B CALDOSE-1 Trial of Lead Asset, Vidofludimus Calcium (IMU-838), in Patients with Moderate-to-Severe Ulcerative Colitis	05/04/23	CI
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Immunic, Inc. Presents Data from Phase 2 Emphasis Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis At Actrims Forum 2023	22/02/23	CI
Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential	17/11/22	CI
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Earnings Flash (IMUX) IMMUNIC Reports Q3 Loss $-0.69, vs. Street Est of $-0.70	03/11/22	MT
Immunic Interim Analysis of Phase 1b Psoriasis Study Shows IMU-935 Severity Reductions in Line With Placebo	21/10/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunic, Inc.

Equities

IMUX

US4525EP1011

Highlights

Filters